Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK."

from http://www.inotekpharma.com/

Research Grants show all

NIH131

Publications show all

Inotek Pharmaceuticals has published 42 articles.

Patents show all

262Applications93Issued

Clinical Trials show all

4Phase 21Phase 11Phase 1/Phase 21Phase 3

SEC Filings show all

8-K3710-Q610-K3D2S-11